59 research outputs found
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
Lacosamide (LCM) is a novel agent that has been developed as an antiepileptic
drug. In vitro studies suggest that LCM modulates voltage-gated sodium channels
by enhancing their slow inactivation. In addition, LCM seems to interact with
collapsin-response mediator protein 2 and thus may mediate neuronal plasticity.
LCM has an elimination half-life of 13 hours, no relevant protein binding, and
does not induce or inhibit enzymes of the cytochrome P450 system. No clinically
significant drug–drug interactions have been discovered as yet.
Experimental data suggest anticonvulsant as well as analgesic effects. Large
clinical studies have demonstrated its efficacy for treatment of patients with
partial seizures. LCM is well tolerated, and the most common adverse events are
unspecific central nervous system and gastrointestinal effects such as
dizziness, vertigo, nausea, and headache. LCM is approved for treatment of
partial seizures with or without secondary generalization in the United States
and the European Union within a dose range of 200 to 400 mg per day,
administered twice daily. In addition to the oral formulations, an intravenous
infusion solution is available
Pregabalin-associated acute psychosis and epileptiform EEG-changes
SummaryPregabalin is a novel anticonvulsive and analgesic drug that has been marketed in Europe for more than a year. The typical side effects are dizziness, somnolence and weight gain. We present a patient who, after unintended rapid up-titration of pregabalin, experienced psychotic symptoms associated with rhythmic EEG-changes resolving completely after discontinuation of pregabalin and benzodiazepine administration
Making SENSE - Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. Methods OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Results Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p < 0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. Conclusions Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. Trial registration Registered in July 2016 at clinicaltrials.gov (NCT02847442)
Volume Estimation of the Thalamus Using Freesurfer and Stereology: Consistency between Methods
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
Seizure cluster: Definition, prevalence, consequences, and management
•Seizure clusters are common in patients with refractory epilepsy.•There is no agreed upon definition for seizure clusters.•Rescue medications are underutilized in seizure clusters.•Non-rectal, non-IV benzodiazepines are safe and effective in the outpatient management of seizure clusters.
To summarize definitions, prevalence, risk factors, consequences, and acute management of seizure clusters using rescue medications.
We searched MEDLINE for studies that assessed definitions, clinical characteristics, outcomes, and use of rescue medication for aborting seizure clusters.
Different clinical and statistical definitions for seizure clusters have been proposed, including: ≥3 seizures in 24 h, ≥2 seizures in 24 h, and ≥2 seizures in 6 h. Most studies of seizure clusters have been conducted in tertiary epilepsy centers, with refractory epilepsy patients. Patients with severe and poorly controlled epilepsy are more likely to experience seizure clusters.
Seizure clusters can result in increased health care utilization and have negative impact on the quality of life of patients and caregivers. Use of benzodiazepine rescue medications in acute management of seizure clusters can help avoid progression to status epilepticus and reduce emergency room visits. Rescue medications are underutilized in seizure clusters. Currently, rectal diazepam gel is the only FDA approved rescue medication for seizure clusters. In addition, buccal midazolam is approved in European countries for treatment of prolonged seizures. However, various non-rectal non-IV benzodiazepines are safe and effective in treating acute seizures and clusters. Most patients and caregivers preferred non-rectal routes.
Identifying patients that are at high risk for seizure clusters, providing them with formal action plans and educating them about use of rescue medication for seizure clusters can help ameliorate the outcomes in this group of epilepsy patients
- …